Genetic Technologies Releases Investor Presentation Report

  • Mar 20, 2019 AEDT
  • Team Kalkine
Genetic Technologies Releases Investor Presentation Report

Molecular Diagnostic Company Genetic Technologies Limited (ASX: GTG) is an ASX and NASDAQ (GENE) listed company with specialization in women’s health through its predictive testing and assessment tools. Its product BREVAGenplus® helps in assessing non-hereditary breast cancer. It is marketed to healthcare professionals at breast healthcare and imaging centres. 

Today, on March 20, 2019, Genetic Technologies announced investor presentation report. The company has 20 years of experience in bringing genomics products to the market. It is currently developing and commercialising a suite of genetic risk assessment products to prevent morbidity and mortality across a range of diseases. It has a progressive R&D and commercialisation partnership with the universities, research organisations and companies exploring new delivery technologies for genomic solutions.

Genetic Technologies has two corporate centres i.e. Genetic Technologies Limited Melbourne, Victoria, Australia and Phenogen Sciences Inc. Charlotte, North Carolina, U.S.

Its Australian centre has technical and corporate support facilities with the laboratory globally certified to RCPA, CLIA, NATA, and ISO. Its United States centre comprised of sales and marketing, customer support, reimbursement management and sample accessioning to Laboratory Information Management System in Australia.

BREVAGenplus® involves a simple cheek swab-based test, which helps in determining women’s risk of developing sporadic breast cancer. It is a first test of its kind as it is clinically validated, which evaluates risk for sporadic breast cancer. It is CLIA-approved and be used in Caucasian, Hispanic and African-American women aged more than 35.

As per the report, one in eight women will suffer breast cancer in their lifetime. 15% of the breast cancers are hereditary with 5% to 10% of breast cancers caused by BRCA1/BRCA2 mutations or 5% to 10% are unknown hereditary cancers. Rest 85% of breast cancer cases are non-hereditary (sporadic) with less than 15% of women who get breast cancer have a family history and only half will test positive for the BRCA mutation. Genetic Technologies’ enhanced breast cancer test covers all non-BRCA related cancers.

Its breast cancer risk assessment test offers the potential for more efficient use of screening resources, such as mammography and MRI, through precision genetic risk profiling across the entire population of women. As per the report, screening programs that test all women at the same intervals will be over-screening seven women and underscreening one woman.

Every year more than 240,000 new breast cancer cases are diagnosed in the U.S., where more than 40,000 patients lose their life. With early detection, more than 95% of such cases can be prevented.

In risk assessment over tumor invasive stages, it is observed that 95% chances of survival for five years with tumors less than 20 mm, 82% chances of survival for tumors between 20mm and 50 mm, and 63% chances of survival for tumors more than 50 mm. Breast cancer develops before it is detected, therefore, it is suggested as “Know Your Risk”. Hence, an early detection results in a better outcome of the treatment.

On stock information, Genetic Technologies’ share last traded at $0.008 on March 20, 2019, with the market capitalisation of ~$21.15 million. Its 52-week high was reported at $0.017 and 52-week low at $0.006 with the average volume of 2,764,012. Its absolute return for five years, one year and three months are -86.67%, -30.43%, and 33.33%, respectively.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

 

All pictures are copyright to their respective owner(s).Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.

 

There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

CLICK HERE FOR YOUR FREE REPORT!
   
x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK